A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

NCT04869228 | Terminated Phase 3

• 1 other identifier: GT0918-MR-3001
• Study Type: interventional
• Target: 380
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease

Conditions

COVID-19

Keywords

COVID-19

Outcome Measures

Primary Outcomes (1)

• Percentage of subjects requiring oxygen by Day 28

  28days

Secondary Outcomes (1)

• Percentage of subjects who experience the events(such as hospitalization,Death etc.) by Day 28. (not applicable for subjects whose countries require mild to moderate COVID-19 patients to be hospitalised, such as COVID-19 patients in mainland China)

  28days

Study Arms (2)

GT0918 in the treatment arm

EXPERIMENTAL

GT0918 tablets : oral, 1 time / day, 2 tablets / time, after meals

Drug: GT0918 tablets or placebo

Placebo in the placebo arm

PLACEBO COMPARATOR

placebo : oral, 1 time / day, 2 tablets / time, after meals

Drug: GT0918 tablets or placebo

Interventions

GT0918 tablets or placebo DRUG

GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals

GT0918 in the treatment arm; Placebo in the placebo arm

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult males age ≥18 years of age at the time of randomization
• Are currently not hospitalized for acute respiratory symptoms (not applicable for subjects whose countries require mild to moderate COVID-19 patients to be hospitalised, such as COVID-19 patients in mainland China)
• The subject's first positive SARS-CoV-2 viral infection test result (using an approved molecular test, or other approved commercial or public health assay on any approved specimen) must be ≤3 days prior to randomization
• Subjects with adequate liver and renal function
• Agree to the collection of nasopharyngeal swabs and venous blood
• The participant or legally authorized representative signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

You may not qualify if:

• Have SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 \< 300, or a respiratory rate ≥30 per minute, or a heart rate ≥125 per minute
• Has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at randomization, due to COVID-19 or requires treatment with supplemental oxygen
• Have known allergies to any of the components used in the formulation of the study drug or placebo
• Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) requiring systemic therapy and that in the opinion of the investigator could constitute a risk to the subject or study assessments when taking study drug or placebo
• Have any co-morbidity anticipated to require surgery within \<7 days, or that is considered life threatening within 30 days
• Have received treatment with the anti-androgen agents or 5-alpha reductase inhibitors within 3 months of the first dose
• Prior, current, or planned future use of any of the following treatments at screening: COVID-19 convalescent plasma, mAbs against SARS-CoV-2, IVIG (any indication), where prior use is defined as the past 30 days or less than 5 half-lives of the investigational product (which is longer) from screening
• Are investigator site personnel directly affiliated with this study
• Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days prior to randomization

Sponsors & Collaborators

• Suzhou Kintor Pharmaceutical Inc,: lead

Study Sites (1)

Hospital Santa Paula

São Paulo, São Paulo, 04556-100, Brazil

Location

MeSH Terms

Conditions

COVID-19

Interventions

proxalutamide

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Cristhieni Rodrigues

  Hospital Santa Paula

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2021
• First Posted: May 3, 2021
• Study Start: August 4, 2021
• Primary Completion: September 2, 2022
• Study Completion: August 2, 2023
• Last Updated: August 18, 2023

Record last verified: 2023-08

Locations

BR (1)